Source Pravda.Ru

Epix disappointed at its depression drug

Epix Pharmaceuticals Inc is going to stop further development of its depression drug, which failed to show sufficient effectiveness in a recent mid-stage trial, sending its shares down 32 percent.

While the drug, PRX-00023, showed a good safety and tolerability profile, the overall results of the trial were disappointing, Chief Executive Michael Kauffman said in a statement.

The drug, which was the most advanced in Epix's pipeline, had already failed to prove effective for general anxiety disorder in 2006, following which the company investigated it as a treatment for major depressive disorder.

Epix has other compounds in its pipeline that it is investigating as treatments for Alzheimer's disease and pulmonary blood pressure.

Epix sells Vasovist, an imaging agent, outside the United States. The company is awaiting U.S. approval for the product and is still struggling with regulatory obstacles.

It plans to refile a marketing application with the U.S. Food and Drug Administration in mid-2008.

Shares of the company were trading at $2.10 before the bell. They closed at $3.08 Wednesday on Nasdaq.

The discovery of the submarine has unveiled a few "inconsistencies." For example, how can one explain the fact that the sub was found where it needed to be searched for from the start?

Argentina hides the truth about the death of San Juan submarine
Comments
Russia close to recognising Donetsk and Luhansk republics after Donbass elections
Unemployment in Russia hits record high of 15 percent
Third Rome and geopolitics of Orthodox schism
Putin wants Russian army rearmed almost completely by 2021
Japan ratifies agreement to supply weapons and ammo to warring states
Argentina hides the truth about the death of San Juan submarine
Argentina hides the truth about the death of San Juan submarine
Putin and Erdogan launch first section of TurkStream pipeline in Istanbul
Why Trump tries to re-industrialize America
Why Trump tries to re-industrialize America
Unemployment in Russia hits record high of 15 percent
Kuril Islands dispute between Russia and Japan: The impossible is impossible
Russia to ban capture of killer whales and belugas in 2019
North Korea destroys security points in demilitarised zone
Russia to ban capture of killer whales and belugas in 2019
Third Rome and geopolitics of Orthodox schism
Five years after Maidan revolution, Ukraine remains one of Europe's most corrupt states
The Amazon and the New Conquistadores
Brexit: The UK's misunderstanding of Democracy
The Amazon and the New Conquistadores
The Amazon and the New Conquistadores